Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2010 - 2026)

Jazz Pharmaceuticals' Cost of Revenue history runs 17 years deep, the most recent figure standing at $134.1 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 28.2% year-over-year to $134.1 million; the TTM figure through Mar 2026 stood at $532.8 million (up 17.14% YoY), while the FY2025 annual figure was $503.3 million, up 12.92% from the prior year.
• Cost of Revenue for Q1 2026 stood at $134.1 million, down from $153.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $167.4 million in Q4 2022, with the low at $95.5 million in Q1 2024.
• The 5-year median for Cost of Revenue is $116.3 million (2025), against an average of $121.1 million.
• The sharpest annual moves came in 2022 and 2023: Cost of Revenue soared 186.85% in 2022, then slumped 35.92% in 2023.
• Jazz Pharmaceuticals' Cost of Revenue stood at $167.4 million in 2022, then tumbled by 35.92% to $107.2 million in 2023, then gained by 20.02% to $128.7 million in 2024, then climbed by 19.28% to $153.5 million in 2025, then decreased by 12.65% to $134.1 million in 2026.
• Business Quant data shows JAZZ's Cost of Revenue at $134.1 million in Q1 2026, $153.5 million in Q4 2025, and $128.9 million in Q3 2025.